Hyperthyroidism

Hyperthyroidism – Medical Student Study Guide

Definition

Hyperthyroidism is a clinical state of excess thyroid hormone action at the tissue level resulting from inappropriately increased synthesis and secretion of thyroid hormones (T3 and/or T4) by the thyroid gland. It is distinguished from thyrotoxicosis, which refers more broadly to the clinical syndrome of hormone excess from any source (endogenous or exogenous).

Epidemiology

Hyperthyroidism is a common endocrine disorder, with Graves' disease as the leading cause in iodine-sufficient regions. Women are affected far more frequently than men, particularly between ages 20–50. Prevalence increases with age and in populations with autoimmune disease clustering (e.g., type 1 diabetes, vitiligo, pernicious anemia). Iodine intake patterns modify the spectrum of disease: Graves' disease predominates in iodine-sufficient areas, while toxic multinodular goiter and toxic adenoma are more frequent in older adults and in areas with previous or current iodine deficiency.^{[2](https://europepmc.org/article/MED/41680939)}

Etiology and Classification

Major etiologies can be grouped by mechanism:

• Increased synthesis and release
  • Graves' disease (TSH receptor–stimulating antibodies)
  • Toxic multinodular goiter
  • Toxic (autonomous) adenoma
  • TSH-secreting pituitary adenoma (secondary hyperthyroidism)
  • hCG-mediated (e.g., gestational thyrotoxicosis, trophoblastic disease)
• Inflammatory/destructive thyroiditis (transient thyrotoxicosis from hormone leakage)
  • Subacute (de Quervain) thyroiditis
  • Painless/silent thyroiditis (often autoimmune or postpartum)
  • Radiation- or drug-induced thyroiditis (e.g., following I-131 therapy)
• Exogenous or ectopic hormone excess
  • Factitious thyrotoxicosis (exogenous thyroid hormone intake)
  • Struma ovarii (ovarian teratoma with thyroid tissue)
  • Ectopic thyroid carcinoma metastases producing hormone

Pathophysiology

Thyroid hormones (T3 and T4) increase basal metabolic rate and potentiate catecholamine action. Excess hormone leads to systemic hypermetabolism, increased oxygen consumption, and upregulated Na+/K+ ATPase activity, particularly in heart, skeletal muscle, liver, and CNS. Elevated T3/T4 enhance β-adrenergic receptor expression and sensitivity, explaining many cardiovascular and neuropsychiatric manifestations.

In Graves' disease, thyroid-stimulating immunoglobulins (TSI or TRAb) bind and activate the TSH receptor, causing diffuse glandular hyperplasia and increased hormone synthesis. Extrathyroidal manifestations (Graves' ophthalmopathy and dermopathy) result from autoimmune activation of orbital fibroblasts and dermal fibroblasts, with glycosaminoglycan accumulation and tissue edema.^{[1](https://europepmc.org/article/MED/41582113)}

In toxic nodular disease, activating mutations in TSH receptor or Gs protein create autonomous nodules that produce thyroid hormone independently of TSH regulation. In thyroiditis, preformed hormone leaks due to follicular destruction; synthesis is actually reduced, so radioiodine uptake is low and the course is typically triphasic (hyperthyroid → hypothyroid → recovery).

Clinical Presentation

The clinical spectrum ranges from subclinical hyperthyroidism (suppressed TSH with normal free T4/T3) to overt hyperthyroidism and life-threatening thyroid storm. Presentation varies by age and etiology.

General Symptoms and Signs

• Metabolic
  • Weight loss despite normal or increased appetite
  • Heat intolerance, increased sweating
  • Fatigue, proximal muscle weakness, hyperreflexia
• Cardiovascular
  • Palpitations, sinus tachycardia
  • Atrial fibrillation or other supraventricular arrhythmias, especially in older adults
  • Widened pulse pressure, high-output heart failure in severe cases
• Neuropsychiatric
  • Anxiety, irritability, emotional lability
  • Tremor (fine, high-frequency), hyperreflexia
  • Insomnia, poor concentration
  • In elderly patients: apathetic hyperthyroidism with depression, lethargy, weight loss but fewer adrenergic signs
• Gastrointestinal
  • Increased stool frequency or diarrhea
  • Mild malabsorption, occasionally hepatic dysfunction
• Reproductive
  • Oligomenorrhea or amenorrhea
  • Reduced fertility, increased miscarriage risk
  • Gynecomastia and reduced libido in men
• Dermatologic
  • Warm, moist skin, fine hair, onycholysis
  • Vitiligo and other autoimmune stigmata, particularly in Graves' disease

Features Specific to Graves' Disease

• Diffuse goiter: symmetrically enlarged, non-nodular thyroid; often with bruit or thrill due to increased vascularity.
• Graves' ophthalmopathy: ocular surface inflammation, periorbital edema, proptosis, extraocular muscle restriction, diplopia, and, in severe cases, compressive optic neuropathy. Imaging (CT/MRI or nuclear) can quantify extraocular muscle inflammation and activity.^{[1](https://europepmc.org/article/MED/41582113)}
• Pretibial myxedema: localized dermopathy with nonpitting, thickened skin and orange-peel appearance over the shins.
• Acropachy: digital clubbing, periosteal bone changes (rare).

Other Etiologic Clues

• Toxic multinodular goiter / toxic adenoma: older age, longstanding nodular goiter, asymmetric enlargement, compressive symptoms; usually no eye or skin changes.
• Thyroiditis: painful thyroid in subacute thyroiditis; painless in silent/postpartum thyroiditis; hyperthyroid phase is transient with later hypothyroid phase.
• Factitious thyrotoxicosis: absence of goiter, suppressed thyroglobulin, low radioiodine uptake, often in healthcare workers or patients with access to thyroid hormone.

Diagnostic Approach

Diagnosis relies on biochemical confirmation of excess thyroid hormone action and subsequent etiologic evaluation.

Initial Laboratory Tests

• Serum TSH: the most sensitive screening test.
  • Primary hyperthyroidism: low or undetectable TSH.
  • Secondary (central) hyperthyroidism: inappropriately normal or elevated TSH despite elevated thyroid hormones.
• Free T4 and Total or Free T3:
  • Overt hyperthyroidism: elevated free T4 and/or T3 with suppressed TSH.
  • T3 toxicosis: elevated T3 with normal T4, suppressed TSH.
  • Subclinical hyperthyroidism: normal free T4/T3 with low TSH.

Tests to Determine Etiology

• Thyroid autoantibodies
  • TSH receptor antibodies (TRAb, including TSI): positive in Graves' disease; useful for diagnosis and for predicting remission/relapse, especially in children.^{[3](https://europepmc.org/article/MED/41806132)}
  • Anti-TPO and anti-thyroglobulin antibodies: support autoimmune thyroid disease but are nonspecific.
• Radioactive iodine uptake (RAIU) and scan
  • Diffuse high uptake: Graves' disease.
  • Focal high uptake in a single nodule with suppressed surrounding tissue: toxic adenoma.
  • Patchy or multinodular uptake: toxic multinodular goiter.
  • Low uptake: thyroiditis, exogenous hormone intake, iodine-induced thyrotoxicosis, struma ovarii.
• Ultrasound
  • Useful for structural assessment, nodules, and vascularity (e.g., increased vascular "thyroid inferno" in Graves').
• Additional tests in selected cases
  • Serum thyroglobulin: low in factitious thyrotoxicosis, high in endogenous disease.
  • hCG levels: to evaluate gestational thyrotoxicosis or trophoblastic disease.
  • Pituitary imaging and α-subunit levels: if central hyperthyroidism suspected.

Hyperthyroidism in Children and Adolescents

Graves' disease is also the leading cause of pediatric hyperthyroidism. Children often present with behavioral changes, declining school performance, weight loss, and tachycardia. Predictors of remission or relapse on antithyroid drug therapy include disease duration, goiter size, antibody titers, and biochemical patterns. Recent work suggests that the free T3/free T4 (FT3/FT4) ratio may help predict remission and relapse risk in pediatric Graves' disease, potentially guiding treatment duration and follow-up intensity.^{[3](https://europepmc.org/article/MED/41806132)}

Management Overview

Management goals are relief of symptoms, normalization of thyroid hormone levels, prevention of complications (especially cardiovascular and skeletal), and definitive control of the underlying cause. Major therapeutic modalities include:

• Symptomatic control: β-blockers.
• Antithyroid drugs (ATDs): thionamides (methimazole, carbimazole, propylthiouracil).
• Radioactive iodine (RAI) ablation.
• Surgery: subtotal or total thyroidectomy.
• Adjuncts in special situations: glucocorticoids, iodinated contrast, potassium iodide, cholestyramine.

Symptomatic Therapy

• β-blockers
  • Propranolol, atenolol, or other β-blockers reduce adrenergic symptoms (palpitations, tremor, anxiety) and modestly inhibit peripheral T4→T3 conversion (propranolol).
  • Indicated in most overtly hyperthyroid patients unless contraindicated (e.g., decompensated asthma, severe bradycardia).

Antithyroid Drugs (ATDs)

ATDs inhibit thyroid hormone synthesis by blocking thyroid peroxidase–mediated iodination of tyrosine residues and coupling reactions; PTU also inhibits peripheral conversion of T4 to T3.

• Methimazole (MMI)
  • First-line in most adults and children with Graves' disease due to once-daily dosing and better safety profile.
  • Dosing is weight- and severity-based; titrated to maintain euthyroidism.
• Propylthiouracil (PTU)
  • Preferred in the first trimester of pregnancy or in thyroid storm when rapid T3 reduction is required.
  • Higher risk of hepatotoxicity; not preferred for long-term use if alternatives exist.
• Monitoring and duration
  • Monitor TSH, free T4, and sometimes T3 every 4–6 weeks initially, adjusting dose to avoid hypothyroidism.
  • For Graves' disease, typical course is 12–18 months, with evaluation of TRAb levels and clinical status to decide on continuation vs definitive therapy.
  • In children, predictive markers (including FT3/FT4 ratio and TRAb) may inform likelihood of remission.^{[3](https://europepmc.org/article/MED/41806132)}
• Adverse effects
  • Common: rash, pruritus, mild GI upset, arthralgia.
  • Serious: agranulocytosis, hepatotoxicity, vasculitis (rare). Patients must be educated to report fever, sore throat, or jaundice promptly.

Radioactive Iodine (RAI) Therapy

RAI (I-131) is a definitive therapy that selectively ablates thyroid tissue through β-emission after uptake via the sodium-iodide symporter.

• Indications
  • Adults with Graves' disease who prefer definitive therapy or have ATD intolerance/relapse.
  • Toxic multinodular goiter or toxic adenoma, especially in older or high-surgical-risk patients.
• Contraindications
  • Pregnancy and breastfeeding.
  • Relative: active moderate-to-severe Graves' ophthalmopathy (may worsen eye disease).
• Considerations
  • Pre-treatment with ATDs may be used in high-risk patients, but ATDs are often stopped several days before RAI.
  • Hypothyroidism is common post-RAI and is usually the intended outcome, requiring lifelong levothyroxine replacement.
  • Glucocorticoids may be given prophylactically in patients with ophthalmopathy to reduce the risk of exacerbation.^{[1](https://europepmc.org/article/MED/41582113)}

Surgical Management

Thyroidectomy offers rapid and definitive treatment but carries operative risks.

• Indications
  • Large goiter with compressive symptoms or substernal extension.
  • Suspicion or presence of thyroid malignancy.
  • Contraindication or refusal of ATDs and RAI.
  • Pregnancy with poorly controlled hyperthyroidism on low/moderate ATD doses.
• Preoperative preparation
  • Render patient as close to euthyroid as possible with ATDs and β-blockers.
  • Administer iodine (e.g., Lugol's solution) short term preoperatively to reduce gland vascularity.
• Complications
  • Hypoparathyroidism (transient or permanent).
  • Recurrent laryngeal nerve injury (hoarseness, vocal cord paresis).
  • Postoperative bleeding and airway compromise.

Management of Specific Etiologies

• Graves' disease
  • First-line options: ATDs, RAI, or surgery; choice depends on age, comorbidities, pregnancy status, goiter size, and patient preference.
  • Ophthalmopathy may influence therapy choice; RAI can worsen orbitopathy, whereas ATDs or surgery are preferred in significant eye disease.^{[1](https://europepmc.org/article/MED/41582113)}
• Toxic multinodular goiter / toxic adenoma
  • RAI or surgery are preferred definitive options.
  • ATDs can stabilize patients prior to definitive treatment or for those who are poor candidates for RAI or surgery.
• Thyroiditis
  • Typically self-limited; treat with β-blockers for hyperadrenergic symptoms.
  • Subacute painful thyroiditis may require NSAIDs or glucocorticoids.
  • ATDs are not effective because hormone synthesis is not increased.
• Factitious thyrotoxicosis
  • Identify and stop exogenous thyroid hormone.
  • β-blockers for symptomatic relief.

Complications of Hyperthyroidism

• Cardiovascular
  • Atrial fibrillation and other arrhythmias, increased stroke risk.
  • Worsening angina and precipitated heart failure in predisposed patients.
• Skeletal
  • Accelerated bone turnover, osteopenia/osteoporosis, increased fracture risk.
• Neuropsychiatric
  • Cognitive impairment, mood disorders, rarely psychosis.
• Reproductive
  • Infertility, pregnancy loss, fetal and neonatal thyroid dysfunction if maternal Graves' antibodies cross the placenta.
• Thyroid storm
  • Acute, life-threatening exacerbation with hyperpyrexia, delirium, severe tachyarrhythmias, heart failure, and multiorgan dysfunction; precipitated by surgery, infection, trauma, or iodine load.

Hyperthyroidism, Iodine Status, and Public Health

Iodine intake strongly influences thyroid disease patterns at the population level. Universal salt iodization programs have effectively reduced iodine deficiency disorders but must be balanced to avoid iodine excess, which can trigger autoimmune thyroid disease and alter the prevalence of hyperthyroidism and hypothyroidism in susceptible populations.^{[2](https://europepmc.org/article/MED/41680939)} Understanding regional iodine status is important when interpreting thyroid function tests and goiter prevalence in epidemiologic and clinical contexts.

Key Clinical Pearls for Exams and Practice

• Always start evaluation with TSH; if suppressed, check free T4 and T3 to distinguish overt from subclinical hyperthyroidism.
• Graves' disease: diffuse goiter, ophthalmopathy, positive TRAb, and high diffuse RAI uptake; it is the prototypical cause of primary hyperthyroidism.
• Toxic multinodular goiter and toxic adenoma: nodular thyroid with focal or patchy high uptake on RAI scan; usually in older patients and iodine-deficient or formerly deficient regions.^{[2](https://europepmc.org/article/MED/41680939)}
• Thyroiditis and factitious thyrotoxicosis: low RAI uptake; think about high thyroglobulin (thyroiditis) vs low thyroglobulin (factitious).
• β-blockers provide rapid symptomatic relief but do not correct the underlying excess hormone production.
• Methimazole is preferred over PTU in most non-pregnant patients due to lower risk of severe hepatotoxicity.
• Always counsel patients on rare but serious ATD side effects, especially agranulocytosis; sudden sore throat or fever warrants immediate evaluation.
• Post-therapy hypothyroidism (after RAI or surgery) is expected and should be treated with levothyroxine replacement.
• In children with Graves' disease, long-term ATD therapy is common, and emerging markers such as the FT3/FT4 ratio and TRAb titers may help predict remission or relapse.^{[3](https://europepmc.org/article/MED/41806132)}
• Iodine status influences the background rates and causes of hyperthyroidism; consider public health factors and population iodine intake when evaluating patients from different regions.^{[2](https://europepmc.org/article/MED/41680939)}